Merck wins EU backing for Keytruda injectable (MRK:NYSE)
Group 1 - Merck announced that the European Medicines Agency (EMA) endorsed an injectable version of its cancer therapy Keytruda (pembrolizumab) [3] - The endorsement comes from an expert panel within the EMA, specifically the Committee for Medicinal Products for Human Use (CHMP) [3] - This development is significant for Merck as Keytruda is a blockbuster drug in its portfolio [3]